2.30Open2.30Pre Close0 Volume155 Open Interest190.00Strike Price0.00Turnover79.62%IV22.84%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0917Delta0.0033Gamma105.76Leverage Ratio-0.1676Theta-0.0147Rho-9.70Eff Leverage0.1022Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet